Home » Psychology news » Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia

Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia

December 13, 2009 by

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia...

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>